Febrile neutropenia in chemotherapy treated small-cell lung cancer patients - Wikidata - awgldk - TriplyDB

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

http://www.wikidata.org/entity/Q35297079

about

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis Outcome of severe infections in afebrile neutropenic cancer patients.Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases.

P2860

Q26786142-B333E0BE-FFD1-4DB0-A434-99D02CBE5958 Q37432031-85EE10D6-D6AF-42C0-823C-C4E10FE8395F Q47185642-60A33489-3275-4621-84E5-BFD097C61FAF

P2860

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

http://www.wikidata.org/entity/Q35297079

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@ast

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@en

type

label

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@ast

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@en

prefLabel

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@ast

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@en

P1433

Q35297079-BD579785-4470-4E18-802D-8736EAB48073

P1476

Q35297079-955DD326-002B-4B31-A125-0E4965589CE1

P2093

Q35297079-1BD373D9-191F-43E6-9357-D933C733B8BD

Q35297079-77FEF9C4-E2E3-4E87-AF68-C027CEAF91B3

Q35297079-7D72E48E-14C2-4C1A-84C9-EFD301A6127B

Q35297079-B90FFB64-2A69-4C44-9342-50CB7C1A018D

Q35297079-E96E2093-36A1-45E9-B387-39F3A35C3381

P2860

Q35297079-0BB314A8-3C6F-46C1-8BA6-72A028FCBF6D

Q35297079-1EB94E18-6D36-4804-B874-82FE0988DF1F

Q35297079-1F695BE3-FDBF-4641-A694-55E180FD04E6

Q35297079-22EF6ED6-74DE-4377-BD1D-2DBCFDDFB5B6

Q35297079-23ED62A6-EE4B-4C7A-9BEE-319366F50C83

Q35297079-396352CD-36F1-4E32-A60C-2C727D4775B2

Q35297079-4A23B9C6-9879-4B57-9226-E9F0E86834D6

Q35297079-4D4D45DF-FD77-409A-97C3-885595375235

Q35297079-4F6E5160-1B80-4933-9719-134BD9C0429C

Q35297079-53D0416C-BBE1-4680-9F32-72D0C3C96330

P304

Q35297079-633295FA-DF24-4DD5-9D15-856F68DFC21E

P31

Q35297079-DCC9D867-5A04-43D5-8B1C-72DCEC9EA15A

P356

Q35297079-97641AF6-CF1E-4721-85AC-9F0ECEEDCDBC

P433

Q35297079-BFD76FA4-E702-4E62-B79A-EED40DC2A344

P478

Q35297079-20EE4E5D-ADE1-43CD-B812-4E2B21548EAF

P50

Q35297079-91F81D57-1C23-40A6-BC35-2D998A44BFA4

P577

Q35297079-E4AC75F9-6D7F-47CC-962A-FC250E5D97E0

P5875

Q35297079-4A85B33E-D3B6-4DDA-8110-3C3352AFF0BE

P698

Q35297079-61F4DA7B-D781-4566-90FB-A6C5BC727FE1

P921

Q35297079-24BCE67A-62B2-4ECC-BA54-837B77B8D2DF

P932

Q35297079-55A21F3A-40EC-4987-86E7-2366C88437EA

P356

P1433

Radiology and Oncology

P1476

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

@en

P2093

Ales Mrhar

http://www.w3.org/2001/XMLSchema#string

Renata Rezonja Kukec

http://www.w3.org/2001/XMLSchema#string

Tanja Cufer

http://www.w3.org/2001/XMLSchema#string

Tomaz Vovk

http://www.w3.org/2001/XMLSchema#string

Viljem Kovac

http://www.w3.org/2001/XMLSchema#string

P2860

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

Comprehensive geriatric assessment and its clinical impact in oncology.

Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

P304

173-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2478/RAON-2014-0050

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273303394

http://www.w3.org/2001/XMLSchema#string

P698

26029029

http://www.w3.org/2001/XMLSchema#string

P921

P932

4387994

http://www.w3.org/2001/XMLSchema#string